Medtronic Set To Pay Part Of $500 Mil. Tyco Tax Settlement
This article was originally published in The Gray Sheet
Executive Summary
The settlement would put to rest a dispute between former Covidien parent company Tyco and the IRS over taxes on intercompany debt. If the settlement is finalized, Medtronic’s share would be about $210 million.
You may also be interested in...
Covidien Completes Pharma Spinoff, Hears From Tyco On Tax Matter
Covidien is now a $9.9 billion, pure-play medical device and supplies company. Separately, the firm could be liable for more than $1 billion in back taxes due to an IRS audit of its former parent, Tyco, though the case is expected to take years to play out in court.
Sumitomo To Re-Prioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.
Lilly, BMS, Microsoft On GenAI’s Machine-First Approach Success, Cell Therapy Use, Regulation
As Eli Lilly chief information and digital officer Rau speaks of generative AI models training humans on drug discovery, Bristol Myers Squibb CDTO Meyers of wearables aiding cell therapy and Microsoft Research India MD Rajamani of interoperability no longer being a huge challenge, a discussion at the BioAsia summit highlights a fundamental shift in R&D approaches.